WhatPeptide

SLU-PP-332

A small-molecule pan-agonist of estrogen-related receptors (ERRα/β/γ) developed at Washington University/St. Louis College of Pharmacy by Thomas Burris. EC₅₀: ERRα ~98 nM, ERRβ ~230 nM, ERRγ ~430 nM (~2- to 4-fold selective for ERRα depending on subtype). CAS: 303760-60-3. Not orally bioavailable — administered IP in animal studies. Successor compound SLU-PP-915 was developed for oral delivery.

Animal studies only Unregulated Exercise Mimetic

Written by WhatPeptide Editorial Team · Last updated 2026-03-18

Half-life

Not characterized in humans. Short duration of action inferred from twice-daily IP dosing in mice.

Dosage range

Mouse studies: 50 mg/kg IP twice daily (Billon et al., ACS Chem Biol 2023 and JPET 2024). Not orally bioavailable. No established human dosing.

Administration

Oral

Research level

Animal only

How SLU-PP-332 works

Activates ERRα, ERRβ, and ERRγ nuclear receptors that regulate mitochondrial biogenesis, fatty acid oxidation, and oxidative muscle fiber specification. Induces exercise-like gene expression programs in skeletal muscle, enhancing endurance capacity and muscle oxidative metabolism without actual physical activity.

Also known as: SLU-PP-332, SLUPP332

Research relevance

Fat Loss
Some relevance 40
Recovery & Healing
Some relevance 20

Side effects & safety

No obvious toxicity at tested doses in animals No human safety data available

Contraindications

No human data — all contraindications theoretical
Hormone-sensitive cancers (theoretical ERR-mediated concern)
Pregnancy

Consult a healthcare provider before use if any of these apply to you.

FAQ

What is SLU-PP-332? +
A small-molecule pan-agonist of estrogen-related receptors (ERRα/β/γ) developed at Washington University/St. Louis College of Pharmacy by Thomas Burris. EC₅₀: ERRα ~98 nM, ERRβ ~230 nM, ERRγ ~430 nM (~2- to 4-fold selective for ERRα depending on subtype). CAS: 303760-60-3. Not orally bioavailable — administered IP in animal studies. Successor compound SLU-PP-915 was developed for oral delivery. Its mechanism of action is based primarily on animal and in-vitro studies.
What is SLU-PP-332 researched for? +
SLU-PP-332 has the strongest research relevance for Fat Loss, Recovery & Healing. Evidence is based primarily on animal and in-vitro studies.
What are the side effects of SLU-PP-332? +
Reported side effects include No obvious toxicity at tested doses in animals, No human safety data available. Key contraindications: No human data — all contraindications theoretical; Hormone-sensitive cancers (theoretical ERR-mediated concern); Pregnancy.
Is SLU-PP-332 FDA approved? +
SLU-PP-332 is not FDA-approved. It is available as a research compound or through compounding pharmacies in some jurisdictions.
How is SLU-PP-332 administered? +
SLU-PP-332 is typically administered via oral route. Researched dosage range: Mouse studies: 50 mg/kg IP twice daily (Billon et al., ACS Chem Biol 2023 and JPET 2024). Not orally bioavailable. No established human dosing.. Half-life: Not characterized in humans. Short duration of action inferred from twice-daily IP dosing in mice..

Explore similar peptides

BAM-15

Animal studies only

Exercise Mimetic

A mitochondrial protonophore uncoupler with EC₅₀ 1.4 μM (~7× more potent than DNP at 10.1 μM). Developed through a multi-institutional collaboration: Webster Santos at Virginia Tech and Kyle Hoehn at the University of Virginia (later UNSW Sydney). Selectively accumulates in lipid-rich tissues (liver, adipose). In mice, reversed diet-induced obesity without hyperthermia or reduced food intake. Continuum Biosciences (co-founded by Santos and Hoehn, 2017) is developing it.

AOD-9604

Preliminary evidence

GH Fragment

A modified growth hormone fragment investigated for lipolysis-related effects without full GH receptor profile. Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

CJC-1295

Moderate evidence

GH Secretagogue

A modified GHRH analog designed to prolong endogenous GH pulse support through albumin binding (DAC form). Originally placed on FDA Category 2 list (September 2023), then removed September 27, 2024 when the nominator withdrew. FDA still lists it under 'Other bulk drug substances that may present significant safety risks.' Regulatory status remains uncertain.

GHRP-2

Moderate evidence

Growth Hormone Releasing Peptide

A potent synthetic GH secretagogue with human endocrine data demonstrating acute GH pulse stimulation.